Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood–tumor barrier penetration unlinked to a passive marker

Neuro-Oncology(2020)10.1093/neuonc/noaa118Source: DataRank Database

HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood–tumor barrier penetration unlinked to a passive marker is a research paper published in Neuro-Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.75)OA: greenTopics (48)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Debbie Wei,Alexandra S. Zimmer ORCID,Christina M. Robinson ORCID,Imran Khan ORCID,Simone Difilippantonio ORCID

Live enrichment

PubMed:32386414 PMC:PMC7690367 OpenAlex:https://openalex.org/W3023281207

National Institutes of Health

Grant: HHSN261200800001E

NCI NIH HHS

Grant: 75N91019D00024

CCR NIH HHS

Grant: HHSN261200800001C

National Cancer Institute

FWCI

1.75

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: public-domain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7690367

publisherhttp://academic.oup.com/neuro-oncology/advance-article-pdf/doi/10.1093/neuonc/noaa118/33364054/noaa118.pdf

publisherhttp://academic.oup.com/neuro-oncology/article-pdf/22/11/1625/34550789/noaa118.pdf

journalhttps://doi.org/10.1093/neuonc/noaa118

Fields of Study

HER2/EGFR in Cancer ResearchBrain Metastases and TreatmentMonoclonal and Polyclonal Antibodies ResearchAnimalsBrain NeoplasmsBreast NeoplasmsCell Line, TumorEndothelial CellsHeterograftsHumansImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabXenograft Model Antitumor Assays

MeSH Terms

TrastuzumabAnimalsBrain NeoplasmsBreast NeoplasmsHumansReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesXenograft Model Antitumor AssaysEndothelial CellsCell Line, TumorHeterografts

Keywords

Brain metastasisAntibody-drug conjugateMedicineMetastasisBreast cancerAntibodyBlood–brain barrierCancer researchVascular permeabilityTrastuzumabPathologyCancerPharmacologyImmunologyInternal medicineMonoclonal antibodyCentral nervous systemBrainPermeabilityBlood-Brain BarrierBlood-tumor BarrierAntibody-tubulysin Conjugate

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (2)

The blood-brain barrier limits the therapeutic efficacy of antibody-drug conjugates in glioblastoma

Neuro-Oncology(2021)

co-citedsame journal

10.1093/neuonc/noab223

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors

N/A

0.593DataRank · unranked

Cell Reports(2022)

co-cited

10.1016/j.celrep.2022.110839

HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood–tumor barrier penetration unlinked to a passive marker

FAIR Checklist

Authors (8)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)

Related Papers (2)